Method of treating neurological disorders with extracts of oleander spp. or oleander spp.

An extract, technology of oleander leaves, applied in the field of preparation, treatment of neurological diseases or disorders, can solve the problem of no dose-related toxicity found

Active Publication Date: 2017-09-15
PHOENIX BIOTECH INC
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No dose-related toxicity was found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating neurological disorders with extracts of oleander spp. or oleander spp.
  • Method of treating neurological disorders with extracts of oleander spp. or oleander spp.
  • Method of treating neurological disorders with extracts of oleander spp. or oleander spp.

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 8

[0069] Example 8 details the in vitro assay used to evaluate the efficacy of the extract, or a composition thereof, in the treatment of stroke-induced ischemic nerve damage. The assay is a brain slice-based assay for oxygenated glucose deprivation (OGD), which is used to induce >50% loss of healthy cortical neurons within 24 hours. A total unfractionated SCF extract of Nerium species such as Nerium oleander was used as a positive control. This total extract was then fractionated according to Example 13 to provide fractions of the extract of Nerium species. Fractions were analyzed according to Examples 6, 14 and 17.

[0070] The HNMR of triterpenes is characterized by 7 methyl signals at upfield, an alkene proton at about 5.3 ppm and an oxidized methine signal at about 3.4 ppm, and an upfield (about 1.0–2.5 ppm) signal Many methylene and methine proton signals for . The HNMR spectrum ( Figures 9B-9I ) indicates that the main components are steroids and triterpenes. No sig...

Embodiment 9

[0075] Example 9 details the in vitro assay used to evaluate the efficacy of the extract in treating Alzheimer's disease. This assay is a brain slice-based assay for APP / Aβ-induced (APP: β-amyloid precursor protein) degeneration of cortical pyramidal neurons. After being cleaved by secretase, APP is broken down into the Aβ peptide, which is believed to be the causative factor in the formation of β-amyloid plaques. The Aβ protein is involved in the formation of β-amyloid plaques and is believed to be the hallmark, if not the cause, of Alzheimer's disease. Biolistic transfection was used to introduce necessary markers such as YFP (labeled yellow fluorescent protein) and disease gene constructs into the same neuronal population of the brain slice. Co-transfection of YFP with APP isoforms resulted in progressive degeneration of cortical pyramidal neurons over a period of three to four days after brain slice preparation and transfection. data( Figures 2A-2C ) showed that oleand...

Embodiment 10

[0079]Example 10 details the assay used to evaluate the efficacy of the extract in the treatment of Huntington's disease. Mutant htt proteins were introduced into high-density, mixed co-cultures of cortical neurons, striatal neurons, and glia by electroporation. Striatal neurons and cortical neurons were transfected with fluorescent proteins of different colors, thereby facilitating the separate identification of different types of neurons in co-cultures. Color fluorescent proteins are fluorescent and "emit" color upon excitation with a light source of the appropriate wavelength. data( Figure 3A-3D ) showed that oleandrin and SCF extract of oleander were more effective than KW6002 (adenosine 2a receptor antagonist) in providing a greater number of surviving neurons. The data also indicate that the SCF extract is more effective than oleandrin alone, suggesting that the extract further comprises one or more therapeutically effective agents other than oleandrin, which could be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method of treating a neurological disorder by administering an extract of Nerium spp. or Nerium chrysanthemum, or a component or subfraction thereof, wherein the extract, or a component or subfraction thereof, does not comprise Oleandrin and Xanthoside B. Alzheimer's disease, Huntington's disease or stroke is treated by administering to a subject a therapeutically effective amount of the extract, or a fraction or subfraction thereof. The extract may be present in pharmaceutical compositions.

Description

technical field [0001] The present invention relates to a method of treating neurological disorders with extracts of Nerium species or Thevetia species, or preparations (compositions, formulations) containing them. In particular, the present invention relates to methods for treating neurological diseases or disorders by administering the extracts to a subject in need thereof. The present invention also includes pharmaceutical compositions containing said extract components or subcomponents and methods for their use and preparation. Background technique [0002] Neurological diseases and disorders affect brain function. Attempts have been made to develop curative or improved treatments for these diseases and disorders; however, while many drug treatments have proven effective for many different diseases and disorders, broad or universal curative treatments have not yet emerged. [0003] Huntington's disease (HD) is a genetic disorder of the brain that affects the nervous sy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/24A61P25/00A61P25/28A61P25/14A61P9/10A61P3/10A61P9/00A61P25/30
CPCA61K31/56A61K31/58A61K36/24A61K45/06A61K2300/00A61K31/704A61K31/7048A61P25/00A61P25/14A61P25/16A61P25/28A61P25/30A61P25/32A61P25/34A61P25/36A61P3/06A61P9/00A61P9/10A61P9/12A61P3/10A61K2121/00A61K2236/39
Inventor O·C·阿丁顿R·A·纽曼
Owner PHOENIX BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap